Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Blenman KRM, et al. Among authors: park t. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. Clin Cancer Res. 2022. PMID: 35377948 Free PMC article. Clinical Trial.
Immunological differences between primary and metastatic breast cancer.
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Szekely B, et al. Among authors: park t. Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399. Ann Oncol. 2018. PMID: 30203045 Free article.
The impact of communication style on patient satisfaction.
Trant AA, Szekely B, Mougalian SS, DiGiovanna MP, Sanft T, Hofstatter E, Silber A, Adelson KB, Chagpar A, Killelea B, Horowitz N, Lannin D, Park T, Corso M, Abraham G, Pollard-Murphy K, Sturrock T, Knill-Selby E, Western A, Servodidio C, Tasoulis MK, Healy B, Hatzis C, Pusztai L. Trant AA, et al. Among authors: park t. Breast Cancer Res Treat. 2019 Jul;176(2):349-356. doi: 10.1007/s10549-019-05232-w. Epub 2019 Apr 25. Breast Cancer Res Treat. 2019. PMID: 31025271
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. Among authors: park t. NPJ Breast Cancer. 2021 Feb 8;7(1):9. doi: 10.1038/s41523-021-00219-7. NPJ Breast Cancer. 2021. PMID: 33558513 Free PMC article.
Characteristics and Long-Term Risk of Breast Angiosarcoma.
Friedrich AU, Reisenbichler ES, Heller DR, LeBlanc JM, Park TS, Killelea BK, Lannin DR. Friedrich AU, et al. Ann Surg Oncol. 2021 Sep;28(9):5112-5118. doi: 10.1245/s10434-021-09689-2. Epub 2021 Feb 18. Ann Surg Oncol. 2021. PMID: 33604827
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. Among authors: park t. NPJ Breast Cancer. 2022 Feb 3;8(1):17. doi: 10.1038/s41523-022-00392-3. NPJ Breast Cancer. 2022. PMID: 35115541 Free PMC article. No abstract available.
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. Among authors: park t. Clin Cancer Res. 2022 Sep 1;28(17):3720-3728. doi: 10.1158/1078-0432.CCR-22-0862. Clin Cancer Res. 2022. PMID: 35903931 Free PMC article. Clinical Trial.
5,264 results